Very interesting news I would of thought before their latest purchase and potential future outlay that they may have considered a T/O of OCC would of been a lot cheaper… Shows that either they are blind or unaware of OCC in the mkt which I find hard to believe with OCC’s latest deal in the USA…
Going by the Company’s above acquisition of Embody Inc Paul Anderson talk of a Significant Re-rate is only a matter of time and we should be $1 plus by all accounts going from what Zimmer Biometric paid for its latest acquisition……
Stem Cell Therapy advancements, page-383
-
- There are more pages in this discussion • 76 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OCC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
36.5¢ |
Change
0.010(2.82%) |
Mkt cap ! $76.40M | |||
| Open | High | Low | Value | Volume |
| 36.0¢ | 37.0¢ | 36.0¢ | $64.31K | 175.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 26656 | 36.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.0¢ | 48304 | 2 |
View Market Depth
| Last trade - 16.10pm 01/07/2024 (20 minute delay) ? |
| OCC (ASX) Chart |